BioAlliance Pharma's LIP phase III pivotal study provides positive preliminary results

BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, is pleased today to announce positive preliminary results in its LIP phase III pivotal study (Lauriad® Immunocompetent Patients Study ). This multicenter randomized, double-blind, placebo controlled study compared the efficacy and safety of a single dose acyclovir Lauriad® 50mg Mucoadhesive Buccal Tablet (MBT) versus matching placebo in patients suffering from recurrent oro-facial herpes.

In the acyclovir Lauriad® patient group among the 722 patients included, the duration of episode from the first prodromal symptoms to healing was significantly decreased>

“These data show that acyclovir Lauriad® brings a strong clinical benefit to patients both in preventing and treating recurrent oro-facial herpes. This trial provides a good basis for a constructive dialog with the regulatory authorities. These results strongly validate the Mucoadhesive Buccal Tablet concept based on early targeted treatment”, said Dominique Costantini, President and CEO of BioAlliance Pharma.